Loading...
•
Dec 30, 2024
Longeveron Q4 2024 Earnings Report
Longeveron reported its third quarter 2024 financial results, highlighting significant progress in clinical trials and a strong financial position.
Key Takeaways
Longeveron Inc. reported a significant increase in total revenue for the first nine months of 2024, up 177% year-over-year to $1.8 million, primarily driven by contract manufacturing services and increased participant demand for the Bahamas Registry Trial. The company also reduced total operating expenses by 14% year-over-year while advancing its clinical pipeline, and expects current cash and cash equivalents to fund operations through Q4 2025.
Phase 2b clinical trial (ELPIS II) for HLHS achieved over 80% enrollment, with FDA confirming it as pivotal for BLA submission.
Positive data from the Phase 2a clinical trial (CLEAR MIND) for Alzheimer's disease was presented at AAIC.
Total revenue for the first nine months of 2024 increased 177% year-over-year to $1.8 million.
Net loss decreased by 23% to $11.9 million for the first nine months of 2024 compared to the same period in 2023.
Revenue by Segment
Forward Guidance
The Company anticipates meeting with the FDA in the first quarter of 2025 to review future clinical and regulatory strategy for Alzheimer's disease. Current cash and cash equivalents are expected to be sufficient to fund Company operations through the fourth quarter of 2025. However, if the ELPIS II trial is successful and BLA enabling activities accelerate, additional financing may be needed.
Positive Outlook
- Current cash and cash equivalents are expected to be sufficient to fund Company through Q4 2025.
- Anticipated meeting with FDA in Q1 2025 to review AD clinical and regulatory strategy.
- Potential BLA filing with FDA in 2026 if ELPIS II trial is successful.
- Intention to seek additional financing/capital raises/non-dilutive funding options to support accelerated activities.
- Continued investment in advancing the clinical pipeline.
Challenges Ahead
- Clinical trial timing for rare diseases is difficult to predict, and enrollment completion for ELPIS II may occur in Q1 2025 instead of end of year.
- Accelerated operating expenses and capital expenditure requirements in 2025 due to BLA enabling activities may necessitate increased spend.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...